CEO at @PeptoneInc | Personal research profile at https://tamiola.com
Image for post
Image for post

We are incredibly excited and proud to be featured by Jeff Bezos’ ‘Day One’ blog.

Recently, we have started working with companies who are developing novel protein-based drugs against the novel coronavirus. We use the AWS Cloud to execute millions of simulations to help identify the most appropriate protein variants (mutants) for successful drug and vaccine development in the fight against COVID-19. The simulations are analysed using artificial intelligence, which builds hypotheses about why and how protein molecules are going to fail.

We are specifically targeting protein developability, as it is one of the most mundane and cost-ineffective steps of protein therapeutic development. We are firmly convinced ‘hit and miss’ approach to protein solubility, anti-aggregation and off-site toxicity can be at large automated and conducted by computers.

Should you be interested to learn more, please go to the original post on Amazon Blog: https://blog.aboutamazon.eu/company-news/how-amazon-web-services-is-supporting-people-and-organizations-in-their-response-to-covid-19


Image for post
Image for post
A cinematic trailer for Peptone Q-BITS Conference.

We are incredibly proud to announce our participation in D-WAVE Q-Bits conference in Milan, Italy on the 25th of March 2019. We will disclose the first fruits of our secretive collaboration with D-WAVE Systems Inc. on modeling the behaviour of intrinsically disordered proteins —’ the next big thing’ in Big Pharma.

Dr. Matt Heberling from our team will give a talk entitled ‘‘Complete Protonation Behaviour of Intrinsically Disordered Proteins through Quantum Annealing”.

You can learn more about the event here.

Ci vediamo a Milano, tutti!


Image for post
Image for post

Ladies and gentlemen, JP Morgan Healthcare Investor Conference 2019 is around the corner and we couldn’t be more excited to join this amazing event that brings the whole healthcare world to San Francisco.

The event starts on the 7th of January, however we will be in the town on the 5th till 12th. We will present our live, adaptive differential evolution demos and walk you through realtime generative peptide design.

It is a busy time for all of us, however, if you happen to be around let’s have a coffee or a drink and talk AI!


Image for post
Image for post

We are incredibly excited to announce our small demo during BioData World Conference in Basel, Switzerland on 28–29 November 2018.

We will present a live, real-time demo of our CassandraAI protein design technology and walk you through the very first results delivered to a Big Pharma client.

Join us in the Startup Zone on the 29th November. Our presentation will start at 1:25pm sharp!


Image for post
Image for post

We are incredibly excited to announce our participation in a AI Italy meetup organized by Marco Scaravelli at Amazon HQ in Milan, Italy.

Kamil will present some of our recent developments in the protein space: “Automated protein drug design, an AI perspective”.

Please follow the link to get more info about the venue and timing.


Image for post
Image for post

What is an “echo chamber”?

Imagine living in a closed system, where information, beliefs, and opinions that comply with personal preferences are augmented and reinforced.

Importantly, any opposing or controversial views, are marginalized or blatantly neglected from any sort of thought process or aspect of life.

Why is this dangerous?

An exposure to biased information strengthens our personal beliefs, while other perspectives become underrepresented, can decrease our understanding of different subject matter immensely, and even undermine our willingness and necessity to try to understand the ‘other side’.

A true problem arises when purposely false information is introduced to an echo chamber. Instead of critically assessing the facts, and questioning the trustworthiness of what is presented, the information is easily accepted as long as it fits the chamber’s preferred form and narrative. …


Image for post
Image for post

What is an “echo chamber”?

Imagine living in a closed system, where information, beliefs, and opinions that comply with personal preferences are augmented and reinforced.

Importantly, any opposing or controversial views, are marginalized or blatantly neglected from any sort of thought process or aspect of life.

Why is this dangerous?

An exposure to biased information strengthens our personal beliefs, while other perspectives become underrepresented, can decrease our understanding of different subject matter immensely, and even undermine our willingness and necessity to try to understand the ‘other side’.

A true problem arises when purposely false information is introduced to an echo chamber. Instead of critically assessing the facts, and questioning the trustworthiness of what is presented, the information is easily accepted as long as it fits the chamber’s preferred form and narrative. …


Image for post
Image for post
A 100,000 node graph that relates 3,900,087 protein fragments through their biophysical features

Synopsis

Combinatorial mutagenesis (CM) is an established approach to protein engineering in pharma and industrial settings. As an extremely laborious process, CM relies on human intuition (rational engineering inspired by existing 3D structures of a protein target) or environmental pressure (directed evolution) to guide the development of new functional variants (mutants) of desired protein target with the goal of enhancing specific property; e.g. thermal stability, solubility or aggregation propensity.

Time inefficiencies, human labor and material costs of CM may translate into major issues in big Pharma: the average drug costs $2.6 B with a 5% success rate for small-molecule drugs and a 13% success rate for protein therapeutic. …


Image for post
Image for post
A 100,000 node graph that relates 3,900,087 protein fragments through their biophysical features

Synopsis

Combinatorial mutagenesis (CM) is an established approach to protein engineering in pharma and industrial settings. As an extremely laborious process, CM relies on human intuition (rational engineering inspired by existing 3D structures of a protein target) or environmental pressure (directed evolution) to guide the development of new functional variants (mutants) of desired protein target with the goal of enhancing specific property; e.g. thermal stability, solubility or aggregation propensity.

Time inefficiencies, human labor and material costs of CM may translate into major issues in big Pharma: the average drug costs $2.6 B with a 5% success rate for small-molecule drugs and a 13% success rate for protein therapeutic. …


Image for post
Image for post
A 100,000 node graph that relates 3,900,087 protein fragments through their biophysical features

Synopsis

Combinatorial mutagenesis (CM) is an established approach to protein engineering in pharma and industrial settings. As an extremely laborious process, CM relies on human intuition (rational engineering inspired by existing 3D structures of a protein target) or environmental pressure (directed evolution) to guide the development of new functional variants (mutants) of desired protein target with the goal of enhancing specific property; e.g. thermal stability, solubility or aggregation propensity.

Time inefficiencies, human labor and material costs of CM may translate into major issues in big Pharma: the average drug costs $2.6 B with a 5% success rate for small-molecule drugs and a 13% success rate for protein therapeutic. …

Get the Medium app

A button that says 'Download on the App Store', and if clicked it will lead you to the iOS App store
A button that says 'Get it on, Google Play', and if clicked it will lead you to the Google Play store